FindTrial
Sign In

Positron emission tomography scan

DIAGNOSTIC_TEST5 trials

Sponsors

VA Office of Research and Development, Miguel Ángel Mendoza Meléndez, University Hospital, Toulouse, Blue Earth Diagnostics

Conditions

Inhalant Use DisorderPositron Emission TomographyProfound Hearing ImpairmentProstate Cancer

Phase 3

Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence
CompletedNCT04186845
Blue Earth DiagnosticsProstate Cancer
Start: 2020-05-04End: 2021-04-28Updated: 2025-09-22
Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.
CompletedNCT04186819
Blue Earth DiagnosticsProstate Cancer
Start: 2020-03-02End: 2021-06-21Updated: 2025-02-26

Unknown Phase

Brain Nicotine Receptor Density in Veteran Smokers
CompletedNCT01721473
VA Office of Research and DevelopmentPositron Emission Tomography
Start: 2012-01-01End: 2016-06-30Updated: 2019-10-07
Brain Imaging Studies of the Effect of Inhalant Use Disorder
CompletedNCT02188914
Miguel Ángel Mendoza MeléndezInhalant Use Disorder
Start: 2014-11-01End: 2016-07-30Updated: 2017-08-17
Positron Emission Tomography Imaging of Brain Reorganisation of the Central Auditory Cortex in Asymetrical Profound Deaf Patient With a Cochlear Implantation.
CompletedNCT03117413
University Hospital, ToulouseProfound Hearing Impairment
Start: 2017-11-23End: 2019-03-22Updated: 2026-05-06

Related Papers

How Standard of Truth Methodology Impacts Diagnostic PSMA-Targeting Radiopharmaceutical Evaluation: Learnings from the Phase 3 SPOTLIGHT Study
Diagnostics2025-02-141 citations
<sup>18</sup>F-Flotufolastat Positron Emission Tomography in African American Patients With Suspected Prostate Cancer Recurrence: Findings From the Phase 3 SPOTLIGHT Study.
2024-07-141 citations
True-Positive<sup>18</sup>F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study
Journal of Nuclear Medicine2024-05-234 citations
Impact of standard-of-truth method on evaluation of a diagnostic PET radiopharmaceutical: Learnings from the phase 3 SPOTLIGHT study.
Journal of Clinical Oncology2024-01-291 citations
Impact of <sup>18</sup>F-flotufolastat PET on management of patients with recurrent prostate cancer: Data from the SPOTLIGHT study.
Journal of Clinical Oncology2024-01-29
Quantitative and Qualitative Assessment of Urinary Activity of <sup>18</sup>F-Flotufolastat-PET/CT in Patients with Prostate Cancer: a Post Hoc Analysis of the LIGHTHOUSE and SPOTLIGHT Studies.
2023-11-0610 citations
Diagnostic Performance and Safety of Positron Emission Tomography with <sup>18</sup>F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE).
2023-07-0564 citations
Diagnostic Performance and Safety of &lt;sup&gt;18&lt;/sup&gt;F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT).
2023-04-2646 citations
MP40-13  <sup>18</sup> F-RHPSMA-7.3 DETECTION RATES IN PATIENTS WITH RECURRENCE OF PROSTATE CANCER FOLLOWING PRIMARY TREATMENT WITH RADIATION THERAPY: RESULTS FROM THE SPOTLIGHT STUDY
The Journal of Urology2023-03-23
Detection of true positive M1 lesions by <sup>18</sup>F-rhPSMA-7.3 PET in newly diagnosed prostate cancer: Results from the phase 3 prospective LIGHTHOUSE study.
Journal of Clinical Oncology2023-02-203 citations
PLLBA-02 IMPACT OF <sup>18</sup> F-RHPSMA-7.3 PET ON UPSTAGING OF PATIENTS WITH PROSTATE CANCER RECURRENCE: RESULTS FROM THE PROSPECTIVE, PHASE 3, MULTICENTER, SPOTLIGHT STUDY
The Journal of Urology2022-04-071 citations
Detection rate of <sup>18</sup>F-rhPSMA-7.3 PET in patients with suspected prostate cancer recurrence: Results from a phase 3, prospective, multicenter study (SPOTLIGHT)
Journal of Clinical Oncology2022-02-166 citations
Kinetic analysis and optimisation of <sup>18</sup>F-rhPSMA-7.3 PET imaging of prostate cancer.
2021-04-1213 citations